Preclinical characterization of SHR6390, a novel CDK 4/6 inhibitor, in vitro and in human tumor xenograft models
Inhibition of the cyclin‐dependent kinase (CDK) 4/6‐retinoblastoma (RB) pathway is an effective therapeutic strategy against cancer. Here, we performed a preclinical investigation of the antitumor activity of SHR6390, a novel CDK4/6 inhibitor. SHR6390 exhibited potent antiproliferative activity agai...
Bewaard in:
| Hoofdauteurs: | , , , , , , , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Engels |
| Gepubliceerd in: |
2019
|
| Online toegang: | https://doi.org/10.1111/cas.13957 https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/cas.13957 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|